Adverum Biotechnologies Inc (NASDAQ:ADVM)’s traded shares stood at 73586.0 during the last session, with the company’s beta value hitting 0.75. At the close of trading, the stock’s price was $2.28, to imply an increase of 0.88% or $0.02 in intraday trading. The ADVM share’s 52-week high remains $10.14, putting it -344.74% down since that peak but still an impressive 21.93% since price per share fell to its 52-week low of $1.78. The company has a valuation of $47.63M, with an average of 0.47 million shares in intraday trading volume over the past 10 days and average of 392.08K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Adverum Biotechnologies Inc (ADVM), translating to a mean rating of 1.33. Of 2 analyst(s) looking at the stock, 0 analyst(s) give ADVM a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -2.28.
Adverum Biotechnologies Inc (NASDAQ:ADVM) trade information
After registering a 0.88% upside in the last session, Adverum Biotechnologies Inc (ADVM) has traded red over the past five days. The 5-day price performance for the stock is -8.43%, and -9.16% over 30 days. With these gigs, the year-to-date price performance is -67.29%. Short interest in Adverum Biotechnologies Inc (NASDAQ:ADVM) saw shorts transact 1.84 million shares and set a 5.99 days time to cover.
The extremes give us $2 and $28 for target low and target high price respectively. As such, ADVM has been trading -1128.07% off suggested target high and 12.28% from its likely low.
Adverum Biotechnologies Inc (ADVM) estimates and forecasts
The rating firms project that company’s revenue will grow 1,165.83% compared to the previous financial year.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 8.03% for the past 5-year period. While 2025 is set for a 13.85% return in earnings, projections for the next 5 years are at 19.86% annually.
ADVM Dividends
Adverum Biotechnologies Inc has its next earnings report out on 2025-May-14. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Adverum Biotechnologies Inc (NASDAQ:ADVM)’s Major holders
Adverum Biotechnologies Inc insiders hold 13.10% of total outstanding shares, with institutional holders owning 79.47% of the shares at 91.45% float percentage. In total, 79.47% institutions holds shares in the company, led by TCG CROSSOVER MANAGEMENT, LLC. As of 2024-06-30, the company held over 2.01 million shares (or 12.1873% of shares), all amounting to roughly $13.78 million.
The next major institution holding the largest number of shares is BML CAPITAL MANAGEMENT, LLC with 1.97 million shares, or about 9.4284% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $13.49 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Adverum Biotechnologies Inc (ADVM) shares. Going by data provided on Mar 31, 2025, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 586.25 shares. This is just over 2.81% of the total shares, with a market valuation of $1.34 million. Data from the same date shows that the other fund manager holds a little less at 517.03, or 2.47% of the shares, all valued at about 1.18 million.
